The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions  Anne Vankeerberghen, Harry Cuppens, Jean-Jacques.

Slides:



Advertisements
Similar presentations
Lesson 3: Translation.
Advertisements

Protein Sorting ISAT 351, Spring 2004 College of Integrated Science and Technology James Madison University.
Co-Transporters Na + /Glucose Symport Vibrio cholerae Prokaryote Water-bourne pathogen Produces Cholera Toxin.
Protein Mutations in Disease Lecture 11, Medical Biochemistry.
Lecture 05 – Extracellular Signal Receptors III Lecture 05 – Extracellular Signal Receptors III BIOL 5190/6190 Cellular & Molecular Singal Transduction.
Cystic FibrosisTransmembrane Conductance Regulator and Filamin A Background for “Biochemical Basis of the Interaction between Cystic Fibrosis Transmembrane.
Permeability Of Lipid Bilayer Smaller and more hydrophobic molecules diffuse across membrane more rapidly.
Cystic Fibrosis and Gastric Acid Transport March 11, 2008 CH353 Group Project Sidani et al. 2007, DeltaF508 mutation results in impaired gastric acid secretion,
Preparing for the Exam Question 1:  Amino acid structures and abbreviations. Question 2:  Mechanism of trypsin. Question 3:  Serine protease evolution.
Genes Genomes and Personalized Medicine
Cells Maintain Their Internal Environments
Cytosol Nucleus Mitochondria Secreted ER Golgi Endosome Lysosome Transmembrane.
Transmembrane and GPCR Mohammed Mohammed Khan PhD Scholar- Department of Biochemistry King Abdul-Aziz University.
Intracellular Trafficking
Molecular pathology of Wilson’s disease: A brief
Mark D. Kleven, Caroline A. Enns, An-Sheng Zhang  Gastroenterology 
Cell Communication (Signaling) Part 2
Volume 52, Issue 3, Pages (March 2010)
Figure 2 The unfolded protein response
Ivacaftor potentiation of multiple CFTR channels with gating mutations
Cell Communication (Signaling) Part 2
Analysis of the CFTR gene in Iranian cystic fibrosis patients: Identification of eight novel mutations  Reza Alibakhshi, Roya Kianishirazi, Jean-Jacques.
Adil E. Bharucha, Scott A. Waldman  Gastroenterology 
Volume 47, Issue 1, Pages (July 2007)
Primary Immunodeficiencies
Jue Chen, Gang Lu, Jeffrey Lin, Amy L Davidson, Florante A Quiocho 
Signal transduction and hepatocellular bile acid transport: Cross talk between bile acids and second messengers  Bernard Bouscarel, Spencer D. Kroll,
Cell Communication (Signaling) Part 2
CFTR: Effect of ICL2 and ICL4 amino acids in close spatial proximity on the current properties of the channel  Arnaud Billet, Jean-Paul Mornon, Mathilde.
Cystic Fibrosis: How do CFTR mutations cause cystic fibrosis?
Cholera 12 The American Journal of Medicine
Relationship between Genotype and Phenotype
On the measurement of the functional properties of the CFTR
Great Expectations for PIP: Phosphoinositides as Regulators of Signaling During Development and Disease  Lara C. Skwarek, Gabrielle L. Boulianne  Developmental.
Volume 4, Issue 6, Pages (December 2008)
PKB Binding Proteins Cell
Cystic fibrosis: recent structural insights
Meindert Lamers, Ilana Berlin, Jacques Neefjes  Current Biology 
Maturation of recoded cystic fibrosis transmembrane conductance regulator (CFTR) channels. a) Representative Western blot obtained from HEK293 cells expressing.
Function, pharmacological correction and maturation of new Indian CFTR gene mutations  Himanshu Sharma, Mathilde Jollivet Souchet, Isabelle Callebaut,
Cystic Fibrosis as a Disease of Misprocessing of the Cystic Fibrosis Transmembrane Conductance Regulator Glycoprotein  John R. Riordan  The American Journal.
From ER to Eph Receptors: New Roles for VAP Fragments
Intracellular cAMP signaling by soluble adenylyl cyclase
Volume 64, Issue 4, Pages (October 2003)
Folding of CFTR Is Predominantly Cotranslational
Let's look at cysts from both sides now
Protein Turnover: A CHIP Programmed for Proteolysis
Kenneth Tran, Nicolas P. Smith, Denis S. Loiselle, Edmund J. Crampin 
CFTR: New Members Join the Fold
Schematic diagram of the proposed structure of CFTR
The Nucleotide-Binding Sites of SUR1: A Mechanistic Model
Endocytic trafficking of CFTR in health and disease
Cell Communication (Signaling) Part 2
Theodore R. Rieger, Richard I. Morimoto, Vassily Hatzimanikatis 
Tuning Bulk Electrostatics to Regulate Protein Function
Volume 57, Issue 3, Pages (March 2000)
بسم الله الرحمن الرحيم.
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
From stones to bones: The biology of ClC chloride channels
Relationship between Genotype and Phenotype
Cellular iron metabolism
Volume 57, Issue 3, Pages (March 2000)
Strategies to investigate the mechanism of action of CFTR modulators
A Futile Battle? Protein Quality Control and the Stress of Aging
Proposed pathway for regulated ATP release from human erythrocytes
Reversible Binding of Phosphate
Design Principles of Protein Biosynthesis-Coupled Quality Control
Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations are categorised into six classes. Cystic fibrosis transmembrane conductance regulator.
Novel pharmacological strategies to treat cystic fibrosis
Long-distance signaling
Presentation transcript:

The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions  Anne Vankeerberghen, Harry Cuppens, Jean-Jacques Cassiman  Journal of Cystic Fibrosis  Volume 1, Issue 1, Pages 13-29 (March 2002) DOI: 10.1016/S1569-1993(01)00003-0

Fig. 1 Schematic representation of the CFTR chloride channel. The different domains, transmembrane domain 1 (TMD1) and 2 (TMD2), nucleotide binding domain 1 (NBD1) and 2 (NBD2), the regulatory domain (R), the N-terminal (NH2) and C-terminal (COOH) ends, the PKA (arrowhead) and PKC (arrowhead and underlined) consensus sites and the glycosylation sites present on the fourth extracellular loop are indicated. Journal of Cystic Fibrosis 2002 1, 13-29DOI: (10.1016/S1569-1993(01)00003-0)

Fig. 2 Maturation model of wildtype and F508del CFTR. Both wildtype and F508del CFTR enter the endoplasmic reticulum during co-translational transport processes. Wildtype CFTR then folds, with the aid of chaperone molecules, such as calnexin and Hsp70-CHIP, into a protease resistant form that is able to leave the ER and will further mature in the Golgi-stacks before it reaches the cell surface. Once present at the cell membrane, the protein is recycled through cycles of endo- and exocytosis. The protein is ultimately degraded in lysosomes. The majority of wildtype translation products, and almost all F508del CFTR, is not able to fold into the protease resistant form in the ER and will be degraded by cytosolic proteasomes. Journal of Cystic Fibrosis 2002 1, 13-29DOI: (10.1016/S1569-1993(01)00003-0)

Fig. 3 Model of CFTR channel gating (modified from Gadsby and Nairn [57]). Activation of the CFTR chloride channel starts with phosphorylation of the R domain by protein kinase A. When CFTR is only partially phosphorylated, only the first nucleotide-binding domain will be able to bind and hydrolyze ATP resulting in only brief openings of the chloride channel. When the R domain is fully phosphorylated, binding and hydrolysis of ATP by NBD1 will not only result in opening of the channel but also in binding of ATP at NBD2. In this way, a stabilization of the open state is achieved and long openings of the channel will be observed. When, in a next step, ATP is hydrolyzed at NBD2 and the hydrolyzation products are released at both NBDs, the channel will close. However, as long as the R domain is phosphorylated the cycles of binding and hydrolysis of ATP, and as a consequence, of opening and closing of the channel, can go on. Once the R domain is dephosphorylated by phosphatases, the channel will close and phosphorylation of the R domain by PKA will be necessary in order to activate the channel again. Activated NBDs are lined. Journal of Cystic Fibrosis 2002 1, 13-29DOI: (10.1016/S1569-1993(01)00003-0)

Fig. 4 CFTR and its interacting neighbors. Journal of Cystic Fibrosis 2002 1, 13-29DOI: (10.1016/S1569-1993(01)00003-0)

Fig. 5 Schematic representation of the different classes of CFTR mutations (modified from Moyer et al. [133]). Journal of Cystic Fibrosis 2002 1, 13-29DOI: (10.1016/S1569-1993(01)00003-0)